shine-logo

lutetium-177

Home » lutetium-177

Visit Us at the SNMMI Annual Meeting 2022

The SHINE Technologies team is gearing up for this year’s SNMMI Annual Meeting, June 11-14 in Vancouver, British Columbia. Leading molecular-imaging and nuclear-medicine professionals from every corner of the industry will come together to share in-depth views of the latest research and development, as well as share insights into practical clinical applications. 

2022-09-08T09:07:38-05:00June 10, 2022|Healthier, Blog, 2022|

SHINE Announces Chris Vessell as General Manager of Therapeutics Division

JANESVILLE, Wis., May 23, 2022 – SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, today announced Chris Vessell has joined as General Manager of the Therapeutics Division. In this role, he will be responsible for developing and building the team dedicated to SHINE’s strategy and offerings around non-carrier-added lutetium-177 for cancer therapies.

2022-09-08T09:07:21-05:00May 23, 2022|Healthier, News, News Releases, Therapeutics, 2022|

SHINE, EDH enter distribution agreement for SHINE’s non-carrier-added Lu-177

SHINE Medical Technologies LLC today announced that they have entered into a distribution agreement enabling EDH to act as a SHINE-authorized distributor for selected countries

SHINE, Phoenix merger focused on advancing fusion technology 

JANESVILLE and FITCHBURG, Wis., April 20, 2021 – SHINE Medical Technologies LLC and Phoenix LLC today announced that the companies have completed a merger under which Phoenix has become a wholly owned subsidiary of SHINE.

2021-12-17T17:37:03-06:00April 20, 2021|News, News Releases, Nuclear Fusion, 2021|

SHINE announces weathertight production facility

SHINE Technologies announced that construction of the exterior structure of its first-of-a-kind medical isotope production facility is complete and the building has been certified as weathertight, a major milestone with significance for SHINE.

2021-12-17T17:37:36-06:00March 25, 2021|News, News Releases, 2021|

SHINE breaks ground on HQ and Therapeutics production facility

SHINE Medical Technologies LLC today announced that the company has broken ground on a new 54,000-square-foot facility that will house its corporate headquarters and a large-scale production facility for the Therapeutics division it established last year.

2022-09-08T09:13:45-05:00December 16, 2020|Safer, Healthier, Cleaner, News, News Releases, Therapeutics, 2020|

SHINE announces first sales of n.c.a. Lu-177

SHINE announced that its Therapeutics division has made its first commercial sales of lutetium-177 to multiple customers. Lutetium-177, or Lu-177, is a therapeutic isotope in demand by clinical trial sponsors because of its potential to revolutionize the treatment of cancer patients.

2022-09-08T09:15:17-05:00November 4, 2020|Healthier, News, News Releases, Medical Isotopes, Therapeutics, 2020|

SHINE closes $80-million

SHINE Medical Technologies LLC, a nuclear technology company focused on becoming the world’s leading producer of medical isotopes, announced today that it has closed an $80-million Series C financing. Fidelity Management and Research Company LLC was the largest investor in the round, which also included participation from other new investors and the company’s current investors.

2021-12-16T20:07:17-06:00September 3, 2020|News, News Releases, 2020|
Go to Top